Market Cap : 2.03 B | Enterprise Value : 23.8 B | PE Ratio : At Loss | PB Ratio : |
---|
NYSE:BHC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:BHC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Bausch Health's Enterprise Value for the quarter that ended in Mar. 2022 was $30,250 Mil. Bausch Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 was $905 Mil. Bausch Health's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2022 was 3.05%.
The historical rank and industry rank for Bausch Health's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Bausch Health was 3.89%. The lowest was -8.95%. And the median was 0.37%.
BHC's Earnings Yield (Joel Greenblatt) % is ranked better thanJoel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Bausch Health's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2022 was 24.20%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
The historical data trend for Bausch Health's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Bausch Health's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Bausch Health's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Bausch Healths Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2021 is calculated as
Earnings Yield (Joel Greenblatt) | = | EBIT | / | Enterprise Value |
= | 402 | / | 32067.19966 | |
= | 1.25 % |
Bausch Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $905 Mil.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.
Thank you for viewing the detailed overview of Bausch Health's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Carson Seana | officer: EVP, General Counsel | 400 SOMERSET CORPORATE BLVD BRIDGEWATER NJ 08807 |
Vadaketh Tom George | officer: EVP, Chief Financial Officer | 1727 JOCKEYS WAY YARDLEY PA 19067 |
Mulligan Richard | director | C/O ICAHN CAPITAL LP 767 FIFTH AVENUE, SUITE 4700 NEW YORK NY 10153 |
Munsch Frederick | officer: SVP, Controller and CAO | 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Gordon Joseph F | officer: Pres&Co-Head Bausch&Lomb/Int'l | 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Ackermann Christina | officer: EVP AND GENERAL COUNSEL | C/O BLCO 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Spurr Robert | director, officer: U.S. President-Pharma Business | C/O BAUSCH HEALTH COMPANIES INC. 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Eldessouky Sam | officer: EVP & Chief Financial Officer | C/O BAUSCH HEALTH COMPANIES INC. 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Miller Steven D | director | 16690 COLLINS AVENUE PH SUNNY ISLE BEACH FL 33160 |
Icahn Brett | director | C/O ICAHN ENTERPRISES L.P. 16690 COLLINS AVE., PH SUNNY ISLES FL 33160 |
Paulson John | director | 1133 AVENUE OF THE AMERICAS 33RD FLOOR NEW YORK NY 10036 |
Valueact Holdings Ii, L.p. | director, other: See Remarks | ONE LETTERMAN DRIVE BUILDING D, FOURTH FLOOR SAN FRANCISCO CA 94129 |
Von Eschenbach Andrew C. | director | BAUSCH HEALTH COMPANIES INC. 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Mckenna Mark C. | officer: President, Salix | 400 SOMERSET CORPORATE BOULEVARD BRIDGEWATER NJ 08807 |
Humphries William D. | officer: EVP, COMPANY GROUP CHAIRMAN | C/O STRATA SKIN SCIENCES, INC. 5 WALNUT GROVE DRIVE SUITE 140 HORSHAM PA 19044 |
From GuruFocus
By PRNewswire 03-29-2022
Other Sources
By Zacks 2022-02-14
By Zacks 2022-02-07
By Zacks 2022-02-21
By Zacks 2022-01-12
By Seekingalpha 2022-01-31
By Zacks 2022-01-24
By Zacks 2022-02-24
By Zacks 2022-02-08
By Zacks 2022-01-31
By Zacks 2022-03-22
By Zacks 2022-01-26
By Zacks 2022-03-25
By Zacks 2022-04-05